2024
Investigating Brain State Engagement Variability in Individuals With Opioid Use Disorder Using Naturalistic and Task-Based fMRI Data
Ye J, Mehta S, Peterson H, Ibrahim A, Saeed G, Linsky S, Kreinin I, Tsang S, Nwanaji-Enwerem U, Raso A, Yip S, Tokoglu F, Arora J, Constable R, Barry D, Redeker N, Yaggi H, Scheinost D. Investigating Brain State Engagement Variability in Individuals With Opioid Use Disorder Using Naturalistic and Task-Based fMRI Data. Biological Psychiatry 2024, 95: s6. DOI: 10.1016/j.biopsych.2024.02.022.Peer-Reviewed Original Research
2019
Anhedonia as a Key Clinical Feature in the Maintenance and Treatment of Opioid Use Disorder
Kiluk BD, Yip SW, DeVito EE, Carroll KM, Sofuoglu M. Anhedonia as a Key Clinical Feature in the Maintenance and Treatment of Opioid Use Disorder. Clinical Psychological Science 2019, 7: 1190-1206. PMID: 32042509, PMCID: PMC7009780, DOI: 10.1177/2167702619855659.Peer-Reviewed Original ResearchOpioid use disorderClinical featuresUse disordersHigher anhedonia scoresKey clinical featuresRate of participantsAnhedonia scoresOpioid-dependent sampleOpioid cravingOpioid useTreatment adherenceHealthy controlsSignificant anhedoniaPharmacological interventionsAssessment of anhedoniaMajority of studiesPotential targetAnhedoniaTreatmentTime courseDisordersSignificant knowledge gapsScoresPotential implicationsCritical need
2018
Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder
Carroll KM, Nich C, Frankforter TL, Yip SW, Kiluk BD, DeVito EE, Sofuoglu M. Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder. Drug And Alcohol Dependence 2018, 192: 264-270. PMID: 30300800, PMCID: PMC6203294, DOI: 10.1016/j.drugalcdep.2018.08.019.Peer-Reviewed Original ResearchConceptsOpioid use disorderOral naltrexoneUse disordersAffective symptomsVoucher-based contingency managementDysphoric symptomsAffective distressOral naltrexone treatmentMultiple baseline characteristicsBaseline characteristicsNaltrexone treatmentHigh riskNaltrexoneSomatic symptomsSymptomsContingency managementTreatmentHigh rateDistressSubstantial evidenceTrialsTheoretical benefitsDisordersAffective discomfortParticipantsCan neuroimaging help combat the opioid epidemic? A systematic review of clinical and pharmacological challenge fMRI studies with recommendations for future research
Moningka H, Lichenstein S, Worhunsky PD, DeVito EE, Scheinost D, Yip SW. Can neuroimaging help combat the opioid epidemic? A systematic review of clinical and pharmacological challenge fMRI studies with recommendations for future research. Neuropsychopharmacology 2018, 44: 259-273. PMID: 30283002, PMCID: PMC6300537, DOI: 10.1038/s41386-018-0232-4.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsOpioid use disorderOpioid epidemicTreatment responseTask-based fMRI paradigmsUrgent public health problemMedication-assisted treatmentPrescription opioid usersCurrent opioid epidemicPublic health problemEvidence-based treatmentsPaucity of literatureHeroin cuesOpioid medicationsRelapse rateOpioid systemOpioid usersFuture neuroimaging studiesSignificant individual variabilityHealthcare costsWithdrawal effectsHealthy individualsHealth problemsSystematic reviewExtended abstinenceNeuroimaging studiesThe Cholinergic System as a Treatment Target for Opioid Use Disorder
Jensen KP, DeVito EE, Yip S, Carroll KM, Sofuoglu M. The Cholinergic System as a Treatment Target for Opioid Use Disorder. CNS Drugs 2018, 32: 981-996. PMID: 30259415, PMCID: PMC6314885, DOI: 10.1007/s40263-018-0572-y.Peer-Reviewed Original ResearchConceptsCholinergic systemUse disordersTreatment targetsOpioid use disorder epidemicCentral nervous system functionTreatment of OUDEffects of acetylcholineOpioid use disorderTobacco use disorderNervous system functionOpioid medicationsDegrade acetylcholineCurrent treatmentOpioid overdosesPreclinical studiesMedicationsAcetylcholineCholinesterase inhibitorsAlzheimer's diseaseNew treatmentsAccidental deathGlobal healthTreatmentOUDDisease